The development of biomarkers of radioresistance in head and neck cancer may help personalize treatment. This commentary puts in context the findings of a secondary analysis of NRG/RTOG 9512, a trial of fractionation in T2N0 glottic cancer, which observed that NFE2L2/KEAP1/CUL3 mutations are correlated with local recurrence and disease-free survival.

See related article by Guan et al., p. XX

This content is only available via PDF.
©2025 American Association for Cancer Research
2025
American Association for Cancer Research
You do not currently have access to this content.